Related Experiment Video
Updated: Aug 28, 2025
A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy
Cerebrovascular disease in sickle cell disease
Vafa Alakbarzade1, Chinedu Maduakor2, Usman Khan2
1Department of Neurology, St George's University Hospitals NHS Foundation Trust, London, UK vafa.alakbarzade.10@ucl.ac.uk.
Insights
Sickle cell disease (SCD) patients experiencing acute ischemic stroke require prompt blood transfusions. Intravenous thrombolysis and endovascular thrombectomy are options for select adult patients, but require careful consideration due to potential complications.
Area of Science:
- Neurology
- Hematology
- Genetics
Background:
- Sickle cell disease (SCD) is a prevalent genetic blood disorder globally.
- Cerebrovascular disease is a severe complication of SCD, leading to significant morbidity and mortality.
- Current guidelines recommend immediate transfusion for acute ischemic stroke in SCD patients.
Discussion:
- Intravenous thrombolysis is recommended for adult SCD patients presenting within 4.5 hours of ischemic stroke symptom onset, particularly those with vascular risk factors.
- Endovascular thrombectomy in adult SCD patients warrants careful consideration due to limited data on cerebral vasculopathy's impact on intervention outcomes.
- A practical approach integrating evidence and experience is presented for managing cerebrovascular disease in sickle cell patients.
Key Insights:
- Prompt transfusion is critical for SCD patients with acute ischemic stroke.
- Thrombolysis is a viable option for specific adult SCD stroke patients.
- Cerebral vasculopathy complicates endovascular treatment decisions in SCD.
Outlook:
- Further research is needed to clarify the role of endovascular thrombectomy in SCD patients.
- Developing tailored treatment protocols for cerebrovascular complications in SCD is essential.
- Improved understanding of cerebral vasculopathy in SCD will refine treatment strategies.
Abstract:
Sickle cell disease (SCD) is the most common type of hereditary anaemia and genetic disorder worldwide. Cerebrovascular disease is one of its most devastating complications, with consequent increased morbidity and mortality. Current guidelines suggest that children and adults with SCD who develop acute ischaemic stroke should be transfused without delay. Those with acute ischaemic stroke aged over 18 years who present within 4.5 hours of symptom onset should be considered for intravenous thrombolysis; older patients with conventional vascular risk factors are the most likely to benefit. Endovascular thrombectomy should be considered carefully in adults with SCD as there are few data to guide how the prevalence of cerebral vasculopathy may confound the expected benefits or risks of intervention. We present a practical approach to cerebrovascular disease in sickle cell patients based on the available evidence and our experience.
Related Concept Videos
01:19Imaging Studies VII: Vascular Imaging
01:20Overview of the Vascular System
01:17Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
01:21Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation